HERTHENA-Lung02: Phase III clinical trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC following EGFR TKI therapy | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors2025 · 13 citations
2HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) unresectable locally advanced or metastatic breast cancer.Human Clinical Trial · 2026 · 1 citations
3A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 studyClinical Trial · 2026
4HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.2024 · 2 citations
5Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?2024 · 5 citations

Patritumab deruxtecan (HER3-DXd) in resistant <i>EGFR</i> -mutated ( <i>EGFR</i> m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.2025
Abstract PS5-07-22: Herthena-breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) unresectable locally advanced or metastatic breast cancer2026
Abstract PS5-12-23: Herthena-breast01: a phase 1b/2, multicenter, open-label, dose-finding study to evaluate the safety and antitumor activity of patritumab deruxtecan (HER3-DXd) in HER2+ unresectable locally advanced or metastatic breast cancer2026
A video summary of the DeLLphi-301 study: tarlatamab as a treatment option for small cell lung cancerVideo Journal of Biomedicine · 2026
Benralizumab for eosinophilic asthma: results from the SHAMAL studyVideo Journal of Biomedicine · 2026

More from Video Journal of Biomedicine

More from Chinese University of Hong Kong